Skip to main content

Table 1 GATA3, TRPS1, and MGP expression in breast carcinomas

From: Matrix Gla protein (MGP), GATA3, and TRPS1: a novel diagnostic panel to determine breast origin

 

Subtype

Negative (n/%)

Positive (n/%)

Total (n)

Mild

Moderate

High

GATA3

ER/PR+

37 (6.6)

26 (4.6)

73 (12.9)

429 (75.9)

565

HER2+

81 (23.0)

33 (9.4)

64 (18.2)

174 (49.4)

352

TNBC-NSTs

87 (60.4)

7 (4.9)

8 (5.6)

42 (29.2)

144

TNBC-MBCs

74 (52.9)

30 (21.4)

21 (6.7)

15 (10.7)

140

Total

279 (23.2)

96 (8.0)

166 (13.8)

660 (55.0)

1201

MGP

ER/PR+

59 (10.4)

153 (27.1)

163 (28.8)

190 (33.6)

565

HER2+

31 (8.8)

78 (22.2)

103 (29.3)

140 (39.8)

352

TNBC-NSTs

20 (13.9)

30 (20.8)

44 (30.6)

50 (34.7)

144

TNBC-MBCs

16 (11.4)

25 (17.9)

49 (35.0)

50 (35.7)

140

Total

126 (10.5)

286 (23.8)

359 (29.9)

430 (35.8)

1201

TRPS1

ER/PR+

39 (6.9)

72 (12.7)

141 (25.0)

313 (55.4)

565

HER2+

28 (8.0)

55 (15.6)

92 (26.1)

177 (50.3)

352

TNBC-NSTs

22 (15.3)

22 (15.3)

36 (25.0)

64 (44.4)

144

TNBC-MBCs

3 (2.1)

8 (5.7)

17 (12.1)

112 (80.0)

140

Total

92 (7.7)

157 (13.1)

286 (23.8)

666 (55.4)

1201

  1. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; TNBC, triple-negative breast cancer; NST, no special type; MBC, metaplastic breast carcinoma